DiaCarta Obtains Exclusive License for Non-Invasive Early Detection Colon Cancer Test
DIACARTA INC. (“DIACARTA”) and UNIVERSITY OF POTSDAM (Germany) today announced that the parties have entered into an exclusive license agreement for the development and commercialization of non-invasive early detection of colon cancer from stool samples. University of Potsdam holds awarded patent “Method for Conducting Non-Invasive Early Detection of Colon Cancer/or of Colon Cancer Precursor Cells.” Under the terms of the agreement, DiaCarta will pay Potsdam an upfront payment plus additional payments based upon achievement of commercial milestones. DiaCarta will have exclusive rights to develop and commercialize the test globally.
Some key clinical groundwork has been established by the group to develop the non-invasive diagnostic test that could be used to screen for early colorectal cancer as well as precursor lesions by detecting cancer-initiating mutations associated with colorectal cancer, which was published in Cancer Prevention Research.
“DiaCarta’s XNA Clamping technology to block all the WT-DNA is the most promising tool for the non-invasive early detection of mutations, including from liquid biopsy,” said Dr. Bettina Scholtka, assistant professor at the University of Potsdam and inventor of the patent. “We are very pleased to partner with DiaCarta to accelerate worldwide development and commercialization of Non-Invasive Early Detection of Colon Cancer.”
“With this agreement, DiaCarta now can extend its QClamp® somatic mutation test product line targeting this unmet market,” said Aiguo Zhang, PhD, DiaCarta’s Founder and CEO. “We look forward to working with Dr. Bettina Scholtka and her team at University of Potsdam to move the unique colon cancer early detection program forward as quickly as possible.”
About DiaCarta Inc.
DiaCarta, is an innovative translational genomics and precision molecular diagnostics company located in the San Francisco Bay Area. QClamp® is a rapid, sensitive qPCR based platform for detection of somatic mutations in cancer genes. The technology can also used for mutant DNA enrichment for Sanger and NGS sequencing. HPV QuantiVirus® cervical and head-neck cancer tests are based on branched DNA technology, which allow detection of oncogenic E6/E7 mRNAs from 14 high-risk subtypes and genotyping of HPV 16 and 18, directly from samples without RNA purification and RT-PCR.
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy announced today that the company has developed a novel test to detect the newest COVID-19 Omicron variant, based on its proprietary XNA technology.
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel virology and oncology tests, mourns the passing of Michael “Mike” J. Powell, Ph.D., Chief Scientific Officer of DiaCarta.
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced that its new QuantiVirus™ SARS-CoV-2 Variant Detection Test received the CE/IVD marking and therefore, can now be commercialized within the EU and rest of the world. This new test screens for the SARS-CoV-2 virus and simultaneously identifies and differentiates all the new mutating COVID 19 variants including the Alpha (UK), Beta (S. Africa), Gamma (Brazil), Delta (India), Delta Plus (India), Epsilon (California) and the Kappa (India) variants.
Former AstraZeneca Personalized Healthcare Strategy Leader Named Senior Vice President of Companion Diagnostics at DiaCarta
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, today announced the appointment of Hongjun “Harry” Yang, Ph.D., former Executive Personalized Healthcare Strategy Leader at AstraZeneca, as Senior Vice President of Companion Diagnostics (CDx) at DiaCarta.
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced the publication of a study entitled “A Rapid SARS-CoV-2 Variant Detection by Molecular-Clamping Based RT-qPCR” in MedRxiV that demonstrates the enhanced sensitivity and specificity using its proprietary XNA based Molecular Clamping Technology that uses innovative synthetic Xenonucleic acid molecular oligomers (XNA) that hybridize with target wild-type DNA sequences, acting as molecular clamps, to enable the accurate amplification of mutant sequences only, using quantitative real-time polymerase chain reactions (qPCR).